Hims & Hers Health looked like a growth story, with fresh deals in GLP-1s, peptide plans and global expansion splashed across headlines. Investors who held Hims & Hers Health over the past year are down 39.9%, including dividends. That backward step came even as revenue in Q2 2026 was higher and subscriber numbers were rising, while net income swung to a loss. If you had locked in a position a year ago, what early clues pointed to that disconnect?
Hims & Hers Health is not the only name tied to this theme. Zero in on 36 healthcare AI stocks and compare how each one is priced.
The Argument You Would Have Been Weighing Up On Hims & Hers Health
The shares cost US$47.46 at the start of the period. Anyone looking at Hims & Hers Health then had to decide whether that price already captured the promise of a bigger digital health platform or underplayed some hard regulatory and competitive questions.
The bullish story pointed to a Fair Value of US$85, a price level those projections implied if things went right, built on vertical integration in diagnostics and advanced compounding that was expected to lift user retention and revenue per subscriber.
The bearish view argued for a Fair Value of US$28, based on the risk that tighter data privacy rules and heavier compliance demands would raise marketing and regulatory costs and weaken long term earnings potential.
What The Results Changed For The Hims & Hers Health Thesis
Hims & Hers Health pushed hard on expansion, from the Eucalyptus acquisition and new GLP-1 and peptide plans to AI-heavy infrastructure and financing deals. Those moves lined up with the bullish vision of a broader platform. The numbers told a different story. Revenue in Q2 2026 was US$753.2m versus US$544.8m a year earlier, while net income moved from a profit to a US$86.3m loss and net margin fell from 7.8% to 11.5% negative. The evidence cut both ways.
The lesson to carry elsewhere is about timing of profitability. When a growth story leans on expanding products and new geographies, check whether rising sales come with improving net margin or widening losses. That single line often shows whether the market is paying upfront for scale or for earnings that are already visible.
What You Would Be Paying For In Hims & Hers Health Today
Hims & Hers Health now trades at US$29.13, after the stock fell 39.9% over the past year. The selected Narrative places its Fair Value above the current price and frames that gap around a long runway in digital healthcare and a broadening mix of subscription services.
The Narrative leans on scale, product breadth and rising customer lifetime value. For that higher figure to be reached, a buyer today would need to believe Hims & Hers Health can turn that expanded ecosystem into steadily improving margins and cash generation.
"We believe Hims & Hers Health remains one of the most compelling long-term growth stories in digital healthcare. The company has successfully transitioned from a niche direct-to-consumer telehealth platform into a diversified healthcare ecosystem with expanding offerings across primary care, mental health, dermatology, sexual health, women's health, and obesity management."
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all
Find Your Own Contrarian Opportunity
The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.
- Company 1 - 24% below our estimate - runs a cloud and productivity stack that meters many AI workloads.
- Company 2 - 35% below our estimate - retools valve and pump operations to emphasize higher margin aftermarket services.
- Company 3 - 40% below our estimate - expands protective-film output so higher margin services grow alongside new installers.
Those are three of them. See every one of the 29 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com